Filing Flows

Filing Flows › Syndax Pharmaceuticals (SNDX) › Next earnings date

Syndax Pharmaceuticals (SNDX) earnings: missed the estimate

Syndax Pharmaceuticals (SNDX) reported on Nov 2, 2026 and missed the EPS estimate: −$0.55 against −$0.48 (-13.7%). Revenue was $83.3M for Q3 2026, +82% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result−13.7% vs estimate
Beat rate40%

The last report

Syndax Pharmaceuticals reported revenue of $83.3M for the third quarter 2026 (+82% Y/Y), net loss $49.4M: Product $60.7M, Collaboration Revenue $22.6M. How it makes money → · Every quarter →

Syndax Pharmaceuticals: EPS against the estimate, last 5 reportsSyndax Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.71−$0.70Nov 25−$0.58−$0.78Feb 26−$0.59−$0.48Apr 26−$0.44−$0.55Aug 26−$0.48−$0.55Nov 26
Latest (Nov 26): Estimate −$0.48, Reported −$0.55.
SNDX: the stock's move on each reportSNDX: the stock's move on each reportAug 4, 2026+3.5%Apr 30, 2026-7.4%Feb 26, 2026+4.6%Nov 3, 2025+12.0%

Syndax Pharmaceuticals' latest quarter

Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Syndax Pharmaceuticals beat earnings?

Syndax Pharmaceuticals (SNDX) reported on Nov 2, 2026 and missed the EPS estimate: −$0.55 against −$0.48 (-13.7%).

When does SNDX report earnings?

The next date is not set yet.

Does Syndax Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.